所有人都是平等的，有些人更平等:针对IBD的IL 12和23 -临床观点

IF 6.2 Q1 IMMUNOLOGY

ImmunoTargets and Therapy Pub Date : 2020-11-26 eCollection Date: 2020-01-01 DOI:10.2147/ITT.S282466

André Jefremow, Markus F Neurath

{"title":"所有人都是平等的，有些人更平等:针对IBD的IL 12和23 -临床观点","authors":"André Jefremow, Markus F Neurath","doi":"10.2147/ITT.S282466","DOIUrl":null,"url":null,"abstract":"Abstract Chronic inflammatory diseases like inflammatory bowel diseases (IBD) or psoriasis represents a worldwide health burden. Researchers provided great achievements in understanding the origin of these diseases leading to improved therapeutic options. The discovery of cytokines like tumor necrosis factor-α or transforming growth factor-β are examples for these efforts. Interleukin 12 (IL 12) and interleukin 23 (IL 23) represent different important cytokines in this regard. They both belong to the interleukin 12 family and are related by sharing the subunit p40. Ustekinumab is an antibody that blocks p40 and thereby interleukins 12 and 23. Trials showed promising results in treating IBD patients with this drug. Consequently, new questions arose about the distinct features of IL 12 and 23. This review focuses on these interleukins regarding their functions in the healthy and inflamed gut and provides an overview about the results from in vitro and in vivo studies as well as clinical trials.","PeriodicalId":30986,"journal":{"name":"ImmunoTargets and Therapy","volume":"9 ","pages":"289-297"},"PeriodicalIF":6.2000,"publicationDate":"2020-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/ITT.S282466","citationCount":"16","resultStr":"{\"title\":\"All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective.\",\"authors\":\"André Jefremow, Markus F Neurath\",\"doi\":\"10.2147/ITT.S282466\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Chronic inflammatory diseases like inflammatory bowel diseases (IBD) or psoriasis represents a worldwide health burden. Researchers provided great achievements in understanding the origin of these diseases leading to improved therapeutic options. The discovery of cytokines like tumor necrosis factor-α or transforming growth factor-β are examples for these efforts. Interleukin 12 (IL 12) and interleukin 23 (IL 23) represent different important cytokines in this regard. They both belong to the interleukin 12 family and are related by sharing the subunit p40. Ustekinumab is an antibody that blocks p40 and thereby interleukins 12 and 23. Trials showed promising results in treating IBD patients with this drug. Consequently, new questions arose about the distinct features of IL 12 and 23. This review focuses on these interleukins regarding their functions in the healthy and inflamed gut and provides an overview about the results from in vitro and in vivo studies as well as clinical trials.\",\"PeriodicalId\":30986,\"journal\":{\"name\":\"ImmunoTargets and Therapy\",\"volume\":\"9 \",\"pages\":\"289-297\"},\"PeriodicalIF\":6.2000,\"publicationDate\":\"2020-11-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2147/ITT.S282466\",\"citationCount\":\"16\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ImmunoTargets and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/ITT.S282466\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ImmunoTargets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/ITT.S282466","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 16

摘要

慢性炎症性疾病，如炎症性肠病(IBD)或牛皮癣是世界范围内的健康负担。研究人员在了解这些疾病的起源方面取得了巨大成就，从而改进了治疗方案。细胞因子如肿瘤坏死因子-α或转化生长因子-β的发现就是这些努力的例子。白细胞介素12 (IL 12)和白细胞介素23 (IL 23)是这方面不同的重要细胞因子。它们都属于白细胞介素12家族，并通过共享亚基p40而相互关联。Ustekinumab是一种阻断p40的抗体，从而阻断白细胞介素12和23。试验显示，用这种药物治疗IBD患者有很好的效果。因此，关于IL - 12和IL - 23的不同特征产生了新的问题。本文综述了这些白细胞介素在健康和炎症肠道中的功能，并概述了体外和体内研究以及临床试验的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective.

查看原文本刊更多论文

All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective.

Abstract Chronic inflammatory diseases like inflammatory bowel diseases (IBD) or psoriasis represents a worldwide health burden. Researchers provided great achievements in understanding the origin of these diseases leading to improved therapeutic options. The discovery of cytokines like tumor necrosis factor-α or transforming growth factor-β are examples for these efforts. Interleukin 12 (IL 12) and interleukin 23 (IL 23) represent different important cytokines in this regard. They both belong to the interleukin 12 family and are related by sharing the subunit p40. Ustekinumab is an antibody that blocks p40 and thereby interleukins 12 and 23. Trials showed promising results in treating IBD patients with this drug. Consequently, new questions arose about the distinct features of IL 12 and 23. This review focuses on these interleukins regarding their functions in the healthy and inflamed gut and provides an overview about the results from in vitro and in vivo studies as well as clinical trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ImmunoTargets and Therapy IMMUNOLOGY-

CiteScore

16.50

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Immuno Targets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management. Basic immunology and physiology of the immune system in health, and disease will be also covered.In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.